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Постојат мал број студии кои пријавиле нарушувања на ендокрината функција по долга употреба на агонист 
на гонадотропин – ослободувачки хормон (ГнРХа) кај девојчиња. Овој третман е опишан како безбеден и 
ефикасен од повеќе автори. Прикажуваме случај на невообичаен исход по долготрајна терапија со ГнРХа кај 
девојче со централен предвремен пубертет (ЦПП) од идиопатска или фамилијарна етиологија. Во период од 
4 години, девојчето примало еднаш месечно трипторелин депо. Ние ја испитавме функцијата на тироидната 
жлезда со мерење на серумските нивоа на тиротропин (ТСХ), тироксин (Т4), тироидни антитела и ултразвук 
на тироидната жлезда. На 11 години таа развила блага гушавост презентирана како автоимун тироидит, со 
покачени тироидни антитела и тироидна жлезда типична за Хашимото тироидит. Затоа, предлагаме редовно 
следење на функцијата на тироидната жлезда кај девојчиња со ЦПП пред и за време на терапија со агонист 
на ГнРХ.
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There is a small number of studies that have reported abnormalities in endocrine function after a long-term 
gonadotropin-releasing hormone agonist (GnRHa) treatment in girls. This treatment is considered as safe and 
effective by most authors. We report our second case of unusual outcome of long-term GnRHa therapy in a 
girl with central precocious puberty (CPP) of idiopathic or familial etiology. She has received monthly depot 
of injections of triptorelin for a time period of 4 years. We have examined thyroid function by measuring 
serum levels of thyrotropin (TSH), thyroxine (T4), thyroid antibodies and ultrasound of thyroid gland. At the 
age of 11 years she developed a mild goiter and presented with autoimmune thyroiditis, having elevated thyroid 
antibodies and ultrasound of thyroid gland typical for Hashimoto thyroiditis. Having in mind these two cases, 
we suggest a closer monitoring of thyroid function in girls with CPP, before and during therapy with GnRH 
agonist.
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Introduction
Central precocious puberty (CPP) in 
childhood, of both idiopathic and or-
ganic etiologies are often treated with 
GnRH agonists. This treatment has 
been considered effective for a long 
period of time. It has been stated that 
long treatment in young children with 
CPP is well tolerated1. However, we 
have already reported a case of a girl 
with CPP who developed autoimmune 
thyroiditis after a long-term treatment 
with GnRH agonists2. In addition, there 
were other reports of impaired thyroid 
functions possibly due to onset of au-
toimmune thyroiditis3. We report our 
second case of this possible side effect 
of treatment. 
Case report 
A 4.5-year-old girl presented to our Pedi-
atric Endocrinology Department due to 
premature telarche. Three years later, 
at the age of 7 years, she was admitted 
again with complaints of rapid growth 
of breasts. Pubertal Tanner stage was 
B3P1A1. Her height was 115.5cm (10th 
percentile, standard deviation (SD): -1) 
and weight 22 kg. Based on the height 
and weight the BMI is 16.5, placing the 
BMI-for-age at the 81th percentile. The 
height of the mother was 155 cm and of 
the father was 165 cm. Her target height 
was 154 cm. She was born small for ges-
tational age (weight 2500 g, length 43 
cm) and during the first year of therapy, 
she was growing between the 10th and 
3rd percentile growth curve. Her family 
history revealed that several members 
on the mother’s side have had thyroid 
disease. Her mother had been investi-
gated for CPP, but never treated. The 
girl did not have dysmorphic features 
and her karyotype was normal. Bone 
age was advanced to 8 years and 10 
months. Her blood count was normal, 
as were other laboratory investigations. 
T4 (thyroxine) was 9.8 ug/dl (normal 
range 4.6-12 ug/dl) and thyrotropin was 
4.9 uIU/ml (0.4-4.0) Thyroid antibodies 
were negative. Ultrasound of thyroid 
gland was normal. The standard GnRH 
testing showed levels of FSH 3.3 to 11.1 
mIU/ml and LH levels 0.16 to 8.5 mIU/
ml. Estradiol levels were 70 pg/ml. The 
ultrasound of ovaries was normal with 
a normal size for age. The magnetic 
resonance imaging (MRI) of the brain 
was normal. She was given continu-
ous GnRHa therapy (triptorelin) 3.75 
mg, once a month. She grew at the 3rd 
percentile growth curve, with adequate 
suppression of her pubertal develop-
ment evaluated every month by clini-
cal inspection and every six months for 
gonadotropin suppression. Due to poor 
growth and being SGA, growth hor-
mone treatment was proposed, which 
the parents rejected. At the age of 11 
years she developed a mild goiter and 
presented with autoimmune thyroid-
itis. T4 was 10.5 ug/dl, TSH 10.5 uIU/
mL, thyroid antibodies a-TPO 573 IU/
ml (normal range < 60 U/ml); a-TG 2272 
U/ml (normal range <60 U/ml), ultra-
sound of thyroid showed diffuse glan-
dular enlargement with heterogeneous 
and hypoechoic parenchymal echo pat-
tern, typical for Hashimoto thyroiditis. 
She was administered levothyroxine 50 
micro g/day. Meanwhile the GnRH ag-
onist therapy was discontinued. At the 
age of 13 years, her puberty was com-
pleted, with normal menstrual cycles, 
but unsatisfactory growth and height 
of 142 cm (SD: -2). She still attends reg-
ular controls for her thyroid status.  
Discussion
We report a second case of a girl who 
developed an autoimmune thyroiditis 
after treatment with GnRH agonists 
for idiopathic or familial CPP. Although 
the period of treatment in this case is 
shorter (4 years), compared to our pre-
viously reported case (8 years), the out-
come is similar. Other authors have de-
scribed an autoimmune thyroiditis in a 
9-year-old girl treated with leuprolide 
acetate4. 
Amino et al. reported hypothyroidism 
after treatment with triptorelin5 and 
Miao et al. described three cases of hy-
perthyroidism3. In a comparative study 
of group of children, with CPP and 
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their thyroid outcome after treatment 
with two different GnRHa, Massart et 
al. did not find thyroid dysfunction, ex-
cept for decreased FT3 in both groups. 
So far, there is no evidence of thyroid 
dysfunction during GnRHa treatments 
(leuprolide acetate and triptorelin), 
and has been concluded that through-
out the administration of GnRHa the 
monitoring of thyroid activity is not 
required.6 Some studies show that af-
ter a long term observation, the GnRHa 
treatment in girls with idiopathic CPP 
is safe for the mineral density of the 
bones, the body mass index as well as 
for the reproductive system, and help-
ful in reaching adult height close to 
target height7. Beyond everything, we 
can hypothesize that there can be three 
possible mechanisms for the hyperthy-
roidism. The first one is the influence 
of triptorelin on hyperthyroidism; the 
second one is the GnRHa triptorelin 
induced autoimmune thyroid disease 
(AITD) to destruct the thyroid and the 
third one is the triptorelin that exacer-
bates the previously existed AITD3.
However, this issue is still controver-
sial, and there has been a lot of debate. 
In our two cases, it is important to no-
tice that both girls with CPP, treated 
with GnRH agonists have a family his-
tory of thyroid disease. 
Some other adverse effects of GnRH ag-
onists have been presented. Sometimes 
the use of depot form of GnRHa ago-
nists is complicated by sterile abscess-
es at injection site and anaphylaxis in 
children 8-10.
A transient vaginal withdrawal bleed-
ing after the first injection of the ag-
onist has also been reported 11-13. The 
findings of the study of Yeshaya et al. 
revealed prolonged and recurrent vagi-
nal bleeding in 8 of 28 patients treated 
with triptorelin depot. 14 Other studies 
did not report this phenomenon 12, 15. 
We have observed a transient throm-
bocytopenia in a girl with CPP (results 
not published). Further, a study of 
Warnock et al., where the respondents 
were women who had endometriosis 
treated with GnRH agonist, showed an 
increase in depressive mood symptoms. 
16 In adults too, there is a report of a 
tricuspid valve thrombus associated 
with gonadotropin-releasing hormone 
analogue therapy. It was considered 
to be related to the procoagulant state 
induced by hormonal treatment17. Addi-
tionally, another side effect as pituitary 
apoplexy has been described after ad-
ministration of leuprolide for carcino-
ma of the prostate. 18 The previous case 
that we have described was thought to 
be a coincidence of a drug treatment, 
and the presented case shows that oth-
er cases of the same pathology appear.
Conclusion
Having in mind our two cases of auto-
immune thyroiditis after a long-term 
therapy with GnRH agonist for CPP in 
girls, we suggest close monitoring of 
thyroid function, before and during 
therapy, especially in patients with 
a family history of thyroid disease, as 
well as other autoimmune disease. 
References 
1. Partsch CJ, Heger S, Sippell WG. Man-
agement and outcome of central pre-
cocious puberty. Clin Endocrinol (Oxf) 
2002;56:129-148.
2. Krstevska-Konstantinova M, Jancevs-
ka A, Gucev Z. Autoimmune thyroid-
itis and diabetes mellitus type 1 after 
long-term gonadotropin-releasing 
hormone agonist treatment for cen-
tral precocious puberty: evolution or 
coincidence? J Pediatr Endocrinol Me-
tab 2010;23:403-406.
3. Miao J, Yan Q, Wang L, Wang X. Three 
cases of transient hyperthyroidism 
after triptorelin treatment - case re-
port and literature review. Gynecol 
Endocrinol 2018;34:734-735.
4. Eyal O, Rose SR. Autoimmune thy-
roiditis during leuprolide acetate 
treatment. J Pediatr 2004;144:394-
396.
5. Amino N, Hidaka Y, Takano T, Tat-
sumi KI, Izumi Y, Nakata Y. Possi-
АРХИВИ НА ЈАВНОТО ЗДРАВЈЕ * ARCHIVES OF PUBLIC HEALTH
65
ble induction of Graves’ disease and 
painless thyroiditis by gonadotro-
pin-releasing hormone analogues. 
Thyroid 2003;13:815-818.
6. Massart F, Harrell JC, Federico G, 
Saggese G. Thyroid outcome during 
long-term gonadotropin-releasing 
hormone agonist treatments for idio-
pathic precocious puberty. J Adolesc 
Health 2007;40:252-257.
7. Pasquino AM, Pucarelli I, Accardo F, 
Demiraj V, Segni M, Di Nardo R. Long-
term observation of 87 girls with id-
iopathic central precocious puberty 
treated with gonadotropin-releasing 
hormone analogs: impact on adult 
height, body mass index, bone mineral 
content, and reproductive function. J 
Clin Endocrinol Metab 2008;93:190-
195.
8. Lam C, Tjon J, Hamilton J, Ahmet 
AH. Recurrent anaphylaxis associat-
ed with gonadotropin-releasing hor-
mone analogs: case report and review 
of the literature. Pharmacotherapy 
2006;26:1811-1815.
9. Letterie GS, Stevenson D, Shah A. Re-
current anaphylaxis to a depot form 
of GnRH analogue. Obstet Gynecol 
1991;78:943-946.
10. Miller BS, Shukla AR. Sterile abscess 
formation in response to two sepa-
rate branded long-acting gonadotro-
pin-releasing hormone agonists. Clin 
Ther 2010;32:1749-1751.
11. Kappy M, Stuart T, Perelman A, Clem-
ons R. Suppression of gonadotropin 
secretion by a long-acting gonado-
tropin-releasing hormone analog (le-
uprolide acetate, Lupron Depot) in 
children with precocious puberty. J 
Clin Endocrinol Metab 1989;69:1087-
1089.
12. Partsch CJ, Peter M, Sippell WG, et 
al. Treatment of progressive central 
precocious puberty with leuprorelin 
depot1998.
13. Roger M, Chaussain JL, Berlier P, et 
al. Long term treatment of male and 
female precocious puberty by peri-
odic administration of a long-acting 
preparation of D-Trp6-luteinizing 
hormone-releasing hormone micro-
capsules. J Clin Endocrinol Metab 
1986;62:670-677.
14. Yeshaya A, Kauschansky A, Orvieto R, 
Varsano I, Nussinovitch M, Ben-Rafael 
Z. Prolonged vaginal bleeding during 
central precocious puberty therapy 
with a long-acting gonadotropin-re-
leasing hormone agonist. Acta Obstet 
Gynecol Scand 1998;77:327-329.
15. Oostdijk W, Rikken B, Schreuder S, et 
al. Final height in central precocious 
puberty after long term treatment 
with a slow release GnRH agonist. 
Arch Dis Child 1996;75:292-297.
16. Warnock JK, Bundren JC, Morris DW. 
Depressive symptoms associated with 
gonadotropin-releasing hormone ag-
onists. Depress Anxiety 1998;7:171-177.
17. Basarici I, Belgi A, Yalcinkaya S. Tri-
cuspid valve thrombus: a case report 
associated with gonadotropin-releas-
ing hormone analogue therapy and 
review of the literature. Can J Cardiol 
2008;24:401-403.
18. Morsi A, Jamal S, Silverberg JD. Pi-
tuitary apoplexy after leuprolide 
administration for carcinoma of 
the prostate. Clin Endocrinol (Oxf) 
1996;44:121-124.
Vol.12 No.1 2020
